In Vivo

Deals in Depth July 2023

21 Aug 2023

• By Deanna Kamienski and Maureen Riordan

Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.

In the top July M&A by deal value, Biogen entered into a definitive agreement to acquire Reata Pharmaceuticals for $172.50 per share in cash (a 58% premium), reflecting an enterprise value of approximately $7.3bn. The deal represents the third-largest biopharma M&A of 2023.

Since its founding in 2002, Reata has been dedicated to developing therapeutics for serious and life-threatening diseases, with a focus...